Gadopiclenol as an MRI contrast agent: first benefit assessment of a diagnostic agent

1 July 2024 - For the first time, IQWiG has evaluated a drug that is a diagnostic agent within the ...

Read more →

Polatuzumab vedotin in untreated diffuse large B-cell lymphoma: one step forward, two steps back

2 April 2024 - Roche designed its trial for both approval and health technology assessments but the analyses planned for ...

Read more →

Tebentafusp in uveal melanoma: indication of a considerable additional benefit

 1 March 2024 - Patients with inoperable or metastatic uveal melanoma survive longer with the new therapy than with other therapy ...

Read more →

Patisiran sodium in hereditary transthyretin amyloidosis: less benefit than vutrisiran

1 March 2024 - In 2023, IQWiG found an additional benefit of vutrisiran compared to patisiran sodium based on a study.  ...

Read more →

Significant additional benefit of mavacamten in hypertrophic obstructive cardiomyopathy

1 February 2024 - In a dossier assessment in 2023, an additional benefit could not yet be proven due to unclear ...

Read more →

New orphan drug for a sub-type of acute myeloid leukaemia: G-BA sees significant additional benefit

18 January 2024 - Since July 2023, there has been one in Germany for patients who suffer from acute myeloid leukaemia ...

Read more →

Vosoritide in achondroplasia: indication of an additional clinical benefit for children aged two and over

1 December 2023 - Two small RCTs with children of different ages together make it possible to make one statement: the ...

Read more →

Early benefit assessment: meaningful RCTs are also feasible in late oncological treatment lines

15 November 2023 - Two randomised controlled studies in the third and fourth lines for colorectal and breast cancer each show ...

Read more →

Multiple sclerosis: hardly any evidence for good patient care

4 October 2023 - Even in the final report, many questions about the treatment of relapsing-remitting multiple sclerosis remain unanswered because ...

Read more →

Clinical studies: you can see better with the second arm

6 October 2023 - In a statement to the EMA, the IQWiG emphasised that single-arm studies may be sufficient for ...

Read more →

Orphan drug for multiple myeloma: G-BA must formally certify legally assumed additional benefit

5 October 2023 - Due to legal requirements, the Federal Joint Committee (G-BA) has completed the re-evaluation process for belantamab mafodotin ...

Read more →

How IQWiG assesses – version 7.0 of the method paper comes into force

19 September 2023 - Fundamental revision of the cost benefit assessment and addition of the concept of application-accompanying data collection. ...

Read more →

Lisocabtagene maraleucel in second-line B-cell lymphoma: additional benefit for certain patients

1 September 2023 - On the basis of the available data, there is a hint of a non-quantifiable added benefit ...

Read more →

Do France, Germany, and Italy agree on the added therapeutic value of medicines?

17 August 2023 - The Health Technology Assessment of medicines is performed separately at the country level with some differences, but ...

Read more →

Upadacitinib in active Crohn's disease: no additional benefit proven due to a lack of comparative studies

1 August 2023 - Although biologics have been used in Crohn's disease for over 20 years, there are hardly any studies ...

Read more →